Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: Results from CALGB 9581

Journal of Clinical Oncology

Volumn 29, Issue 23, 2011, Pages 3146-3152

  Niedzwiecki, Donna ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Bertagnolli, Monica M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Warren, Robert S ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Compton, Carolyn C ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Kemeny, Nancy E ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Benson III, Al Bowen ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Eckhardt, S Gail ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Alberts, Steven ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Porjosh, Gity N ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Kerr, David J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Anthony, ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Fields, ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Rougier, Philippe ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Pipas, J Marc ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Schwartz, Joel H ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Atkins, James ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   O'Rourke, Mark ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Perry, Michael C ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Goldberg, Richard M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Mayer, Robert J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   Colacchio, Thomas A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s}   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Southeast Cancer Control Consortium Inc   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Massachusetts General North Shore Cancer Center   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ Southwest Oncology Group   (United States)

^j North Central Cancer Treatment Group Rochester   (United States)

^k Inova Research Center   (United States)

^l DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^m Cancer Centers of the Carolinas   (United States)

ⁿ UNIVERSITY OF MISSOURI   (United States)

^o Birmingham Clinical Trials Unit   (United Kingdom)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q Queen's Cancer Research Institute   (Canada)

^r EORTC DATA CENTER   (Belgium)

^s HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EDRECOLOMAB;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL OBSERVATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 80051809050     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.5357     Document Type: Article

References (44)

1. Jemal A., Siegel R., Ward E., et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Wolmark N., Rockette H., Fisher B., et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993 (Pubitemid 23304611)
3. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Lancet 345:939-944, 1995
4. Haller D.G., Catalano P.J., Macdonald J.S., et al: Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089. Proc Am Soc Clin Oncol 17:256a, 1998 (suppl; abstr 982)
5. Zaniboni A.: Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: Impact on disease-free survival and overall survival. J Clin Oncol 15:2432-2441, 1997
6. O'Connell M.J., Mailliard J.A., Kahn M.J., et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997 (Pubitemid 27020580)
7. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer: International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 17:1356-1363, 1999
8. Wolmark N., Rockette H., Mamounas E., et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559, 1999 (Pubitemid 29517927)
9. QUASAR Collaborative Group, Gray R, Barnwell J, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020-2029, 2007
10. Haller D.G., Catalano P.J., Macdonald J.S., et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 23:8671-8678, 2005 (Pubitemid 46211510)
11. Kuebler J.P., Wieand H.S., O'Connell M.J., et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007 (Pubitemid 46954643)
12. Wolmark N., Wieand S., Kuebler P.J., et al: A phase III trial comparing FU/LV to FU/LV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. J Clin Oncol 26: 1008s, 2008 (suppl; abstr LBA4005)
13. André T., Boni C., Navarro M., et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
14. Adjuvant therapy for patients with colon and rectum cancer. Consens Statement 8:1-25, 1990
15. Benson A.B. 3rd, Schrag D., Somerfield M.R., et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419, 2004 (Pubitemid 41103700)
16. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, v3.2010. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp#site
17. Meyerhardt J.A., Mayer R.J.: Systemic therapy for colorectal cancer. N Engl J Med 352:476-487, 2005
18. Benson A.B. 3rd: The hope for today-the promise for tomorrow: Will oncologists meet the challenge? J Clin Oncol 25:2156-2158, 2007
19. Göttinger HG, Funke I, Johnson JP, et al: The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38:47-53, 1986
20. Adams D.O., Hall T., Steplewski Z., et al: Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci U S A 81:3506-3510, 1984 (Pubitemid 14122703)
21. Herlyn D., Wettendorff M., Schmoll E., et al: Anti-idiotype immunization of cancer patients: Modulation of the immune response. Proc Natl Acad Sci U S A 84:8055-8059, 1987 (Pubitemid 17162819)
22. Mellstedt H., Frödin J.E., Masucci G., et al: Monoclonal antibodies (MAb 17-1A) for the treatment of patients with metastatic colorectal carcinomas. Acta Chir Scand Suppl 549:63-70, 1989 (Pubitemid 19124865)
23. Wadler S.: The role of immunotherapy in colorectal cancer. Semin Oncol 18:S27-S38, 1991 (suppl)
24. Ragnhammar P., Magnusson I., Masucci G., et al: The therapeutic use of the unconjugated monoclonal antibodies (Mab) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma. Med Oncol Tumor Pharmacother 10:61-70, 1993 (Pubitemid 23168715)
25. Maeda M., Shoji M., Kawagoshi T., et al: Distribution of 111In- and 125I-labeled monoclonal antibody 17-1A in mice bearing xenografts of human pancreatic carcinoma HuP-T4. Cancer 73:S800-S807, 1994 (suppl 3)
26. Riethmüller G., Schneider-Gädicke E., Schlimok G., et al: Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma: German Cancer Aid 17-1A Study Group. Lancet 343:1177-1183, 1994 (Pubitemid 24147551)
27. Fleming ID, Cooper JS, Henson DE, et al (eds): AJCC Manual for Staging of Cancer (ed 5). Philadelphia, PA, Lippincott-Raven, 1997
28. Greene FL, Page DL, Fleming ID, et al (eds): AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002
29. Kaplan E.L., Meier P.: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Cox D.R.: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
31. Harrell F.E. Jr, Lee K.L., Califf R.M., et al: Regression modelling strategies for improved prognostic prediction. Stat Med 3:143-152, 1984 (Pubitemid 14052973)
32. Harrell FE: Design: S-plus function for biostatistical/ epidemiological modeling, testing, estimation, validation, graphics, prediction, and typesetting by storing enhanced model design attributes in the fit, 1994. http://lib.stat.cmu.edu/DOS/S/Harrell/
33. Kalbfleisch J.D., Prentice R.L.: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980, pp 163-188
34. Wu Y., Takkenberg J.J., Grunkemeier G.L.: Measuring follow-up completeness. Ann Thorac Surg 85:1155-1157, 2008 (Pubitemid 351381672)
35. Gray R.J.: A class of K-sample tests for comparing the cumulative incidence of a completing risk. Ann Stat 16:1141-1154, 1988
36. Fine J.P., Gray R.J.: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
37. Therneau T.M., Grambsch P.M.: Modeling Survival Data, Extending the Cox Model. New York, NY, Springer-Verlag, 2000, pp 107-111
38. R Development Core Team: R: A language and environment for statistical computing. http://www.R-project.org
39. Fields A.L., Keller A., Schwartzberg L., et al: Adjuvant therapy with the monoclonal antibody edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 27:1941-1947, 2009
40. Punt C.J., Nagy A., Douillard J.Y., et al: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: A randomized study. Lancet 360:671-677, 2002 (Pubitemid 35232335)
41. Niedzwiecki D., Hollis D.: Interpretation of results: Data analysis and reporting of results, in Kelly WK, Halabi S (eds): Oncology Clinical Trials: Successful Design, Conduct, and Analysis. New York, NY, Demos Medical, 2010, pp 184
42. Gunderson L.L., Jessup J.M., Sargent D.J., et al: Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28:264-271, 2010
43. Le Voyer T.E., Sigurdson E.R., Hanlon A.L., et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 21:2912-2919, 2003 (Pubitemid 46621841)
44. Swanson R.S., Compton C.C., Stewart A.K., et al: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10:65-71, 2003